Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Large Growth in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 352,300 shares, an increase of 20.8% from the February 28th total of 291,600 shares. Based on an average daily trading volume, of 141,900 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.6% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on NAUT shares. Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their target price for the company from $2.25 to $1.75 in a research note on Thursday, December 5th.

Insider Activity at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 53,300 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the acquisition, the chief executive officer now owns 10,117,788 shares of the company’s stock, valued at approximately $10,016,610.12. This trade represents a 0.53 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 40.50% of the stock is currently owned by company insiders.

Institutional Trading of Nautilus Biotechnology

Institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in Nautilus Biotechnology in the 4th quarter valued at $28,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Nautilus Biotechnology during the fourth quarter worth approximately $34,000. Squarepoint Ops LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $44,000. SG Americas Securities LLC boosted its stake in Nautilus Biotechnology by 56.3% in the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after purchasing an additional 9,904 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its holdings in shares of Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after purchasing an additional 8,888 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Stock Up 2.5 %

NASDAQ NAUT traded up $0.02 during midday trading on Wednesday, hitting $0.85. The company had a trading volume of 178,897 shares, compared to its average volume of 99,551. The firm has a fifty day simple moving average of $1.40 and a two-hundred day simple moving average of $2.02. Nautilus Biotechnology has a fifty-two week low of $0.81 and a fifty-two week high of $3.09. The stock has a market cap of $107.35 million, a price-to-earnings ratio of -1.52 and a beta of 1.25.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.